Medivation Announces Fourth Quarter and Year-End Financial Results Teleconference on February 29, 2012
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 02/22/12 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss fourth quarter and year-end financial results and provide a general business update on Wednesday, February 29, 2012 at 4:30 p.m. Eastern Time. A press release for the fourth quarter and year ended December 31, 2011 will be released after markets close on February 29, 2012.
Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has the investigational drug MDV3100 in Phase 3 development to treat advanced prostate cancer. For more information, please visit us at .
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101
Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 22.02.2012 - 16:26 Uhr
Sprache: Deutsch
News-ID 1085814
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN FRANCISCO, CA
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 110 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medivation Announces Fourth Quarter and Year-End Financial Results Teleconference on February 29, 2012
"
steht unter der journalistisch-redaktionellen Verantwortung von
Medivation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
